Find participating medical centers and current study status in each of them
Find participating medical centers
-
Home
-
Clinical Study Finder
- LUMINESCE
A clinical trial to look at how safe and effective satralizumab is at reducing certain signs of generalised myasthenia gravis (gMG)
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
Autoimmune Disorder Myasthenia Gravis (IAB) Generalized Myasthenia Gravis (gMG)
Study results
LPS WN42636 LUMINESCE Final Results February 2025 English
(PDF, 0.4 MB)
LPS WN42636 LUMINESCE Final Results February 2025 Brazil Portuguese
(PDF, 0.5 MB)
LPS WN42636 LUMINESCE Final Results February 2025 Danish
(PDF, 0.5 MB)
LPS WN42636 LUMINESCE Final Results February 2025 French
(PDF, 0.5 MB)
LPS WN42636 LUMINESCE Final Results February 2025 German
(PDF, 0.5 MB)
LPS WN42636 LUMINESCE Final Results February 2025 Italian
(PDF, 0.4 MB)
LPS WN42636 LUMINESCE Final Results February 2025 Japanese
(PDF, 0.5 MB)
LPS WN42636 LUMINESCE Final Results February 2025 Korean
(PDF, 0.6 MB)
LPS WN42636 LUMINESCE Final Results February 2025 LATAM Spanish
(PDF, 0.5 MB)
LPS WN42636 LUMINESCE Final Results February 2025 Polish
(PDF, 0.5 MB)
LPS WN42636 LUMINESCE Final Results February 2025 Russian
(PDF, 0.5 MB)
LPS WN42636 LUMINESCE Final Results February 2025 Spain Spanish
(PDF, 0.5 MB)
LPS WN42636 LUMINESCE Final Results February 2025 Turkish
(PDF, 0.5 MB)
LPS WN42636 LUMINESCE Final Results March 2025 China Chinese
(PDF, 0.6 MB)
LPS WN42636 LUMINESCE Final Results March 2025 Taiwan Chinese
(PDF, 0.5 MB)
Explore related studies
For the latest version of this information please go to www.forpatients.roche.com